Last reviewed · How we verify
Experimental: Alpha-blocker group
Alpha-blockers inhibit alpha-adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.
Alpha-blockers inhibit alpha-adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction. Used for Hypertension, Benign prostatic hyperplasia with lower urinary tract symptoms.
At a glance
| Generic name | Experimental: Alpha-blocker group |
|---|---|
| Sponsor | Pedro de Figueiredo Buchalla |
| Drug class | Alpha-blocker |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Urology |
| Phase | FDA-approved |
Mechanism of action
Alpha-blockers selectively block alpha-1 adrenergic receptors, which mediate vasoconstriction and smooth muscle contraction in blood vessels and the prostate. By antagonizing these receptors, they reduce peripheral vascular resistance and relax prostatic smooth muscle, lowering blood pressure and improving urinary flow in benign prostatic hyperplasia.
Approved indications
- Hypertension
- Benign prostatic hyperplasia with lower urinary tract symptoms
Common side effects
- Dizziness
- Headache
- Fatigue
- Orthostatic hypotension
- Syncope
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: Alpha-blocker group CI brief — competitive landscape report
- Experimental: Alpha-blocker group updates RSS · CI watch RSS
- Pedro de Figueiredo Buchalla portfolio CI